Compounds > 4-aminoquinazoline
Page last updated: 2024-11-06

4-aminoquinazoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Aminoquinazoline is a heterocyclic compound that serves as a core structure for numerous drugs with diverse pharmacological activities. Its synthesis often involves the condensation of anthranilic acid with formamide or a related derivative. 4-Aminoquinazoline derivatives have shown promising effects in treating a variety of diseases, including cancer, malaria, and bacterial infections. The presence of the amino group at the 4-position provides a versatile handle for chemical modifications, enabling the development of targeted therapies with enhanced potency and selectivity. The structural features of 4-aminoquinazoline, including its planar aromatic system and the presence of hydrogen bond acceptors, allow for interactions with various biological targets. Ongoing research continues to explore the therapeutic potential of 4-aminoquinazoline derivatives, focusing on improving their efficacy and safety profiles.'

4-aminoquinazoline: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID84759
CHEMBL ID266128
SCHEMBL ID142513
SCHEMBL ID9375368
MeSH IDM0575598

Synonyms (40)

Synonym
AKOS001104743
quinazoline, 4-amino-
4-quinazolinamine
4-aminoquinazoline
4-quinazolineamine
BB 0237720
AF-936/31233025
quinazolin-4-ylamine
nsc288012
15018-66-3
nsc-288012
OPREA1_618867
STK001877
quinazolin-4-amine
CHEMBL266128
EN300-79874
A18225
nsc 288012
FT-0679112
NCGC00346839-01
4B-019
AM20030020
1lq ,
AB03303
SCHEMBL142513
4-amino quinazoline
SCHEMBL9375368
4-quinazolinamine #
DTXSID90164488
mfcd00092016
J-524171
4-quinazolinamine, aldrichcpr
CS-W008984
AC-9148
quinazolin-4(3h)-imine
4-aminoquinazoline;nsc 288012
bdbm50228495
Q27452208
SY101342
Z99599970

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency35.19730.001310.157742.8575AID1259252; AID1259253
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phosphatidylinositol 4-kinase alphaHomo sapiens (human)IC50 (µMol)91.70000.28003.69007.1000AID155650
Phosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)IC50 (µMol)91.70007.10007.10007.1000AID155650
Phosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)IC50 (µMol)91.70007.10007.10007.1000AID155650
Phosphatidylinositol 4-kinase betaHomo sapiens (human)IC50 (µMol)91.70000.01832.45107.1000AID155650
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
phosphorylationPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
signal transductionPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
modulation by host of viral processPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
reorganization of cellular membranes to establish viral sites of replicationPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
endosome organizationPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
Golgi organizationPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
endosome organizationPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
Golgi organizationPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
lysosome organizationPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-kinase betaHomo sapiens (human)
receptor-mediated endocytosisPhosphatidylinositol 4-kinase betaHomo sapiens (human)
signal transductionPhosphatidylinositol 4-kinase betaHomo sapiens (human)
inner ear developmentPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
1-phosphatidylinositol 4-kinase activityPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
kinase activityPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
cadherin bindingPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
1-phosphatidylinositol 4-kinase activityPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
magnesium ion bindingPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
1-phosphatidylinositol 4-kinase activityPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
AP-3 adaptor complex bindingPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
1-phosphatidylinositol 4-kinase activityPhosphatidylinositol 4-kinase betaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
14-3-3 protein bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
cytoplasmPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
cytosolPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase alphaHomo sapiens (human)
focal adhesionPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
membranePhosphatidylinositol 4-kinase alphaHomo sapiens (human)
Golgi-associated vesicle membranePhosphatidylinositol 4-kinase alphaHomo sapiens (human)
extracellular exosomePhosphatidylinositol 4-kinase alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase alphaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
Golgi membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
endoplasmic reticulum membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
cytosolPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
early endosome membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
endosomePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
trans-Golgi networkPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
BLOC-1 complexPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
Golgi membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
mitochondrionPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
lysosomal membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
endosomePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
cytosolPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
dendritePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
cytoplasmic vesiclePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
early endosome membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
growing cell tipPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
presynaptic membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
neuron projectionPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
neuronal cell bodyPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
perikaryonPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
membrane raftPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
trans-Golgi networkPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
endosomePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
Golgi membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
mitochondrial outer membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
endosomePhosphatidylinositol 4-kinase betaHomo sapiens (human)
Golgi apparatusPhosphatidylinositol 4-kinase betaHomo sapiens (human)
cytosolPhosphatidylinositol 4-kinase betaHomo sapiens (human)
rough endoplasmic reticulum membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
perinuclear region of cytoplasmPhosphatidylinositol 4-kinase betaHomo sapiens (human)
membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-kinase betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID155653Binding affinity (Ki) against human phosphatidylinositol 4-kinase1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Purine derivatives as competitive inhibitors of human erythrocyte membrane phosphatidylinositol 4-kinase.
AID551809Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
AID1145385Inhibition of liver dihydrofolate reductase (unknown origin)1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Inhibition of dihydrofolate reductase. Structure-activity correlations of quinazolines.
AID155650Inhibitory activity (IC50) against human phosphatidylinositol 4-kinase at the ATP binding site1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Purine derivatives as competitive inhibitors of human erythrocyte membrane phosphatidylinositol 4-kinase.
AID134245Acute toxicity determined in mice by an LD50 test when administered peritoneally1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Antifolate and antibacterial activities of 5-substituted 2,4-diaminoquinazolines.
AID58164Concentration required for inhibition of rat liver dihydrofolate reductase (DHFR)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Combined distance geometry analysis of dihydrofolate reductase inhibition by quinazolines and triazines.
AID134244Acute toxicity determined in mice by an LD50 test when administered intraperitoneally1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Antifolate and antibacterial activities of 5-substituted 2,4-diaminoquinazolines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (8.89)18.7374
1990's2 (4.44)18.2507
2000's0 (0.00)29.6817
2010's24 (53.33)24.3611
2020's15 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.80 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.44%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (95.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
9-ethyladenine
[no description available]		1.9710
adenine
[no description available]		2.41106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
imidazole
imidazole: RN given refers to parent cpd. 1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.		2.2110imidazole
purine
1H-purine : The 1H-tautomer of purine.. 3H-purine : The 3H-tautomer of purine.. 9H-purine : The 9H-tautomer of purine.. 7H-purine : The 7H-tautomer of purine.		1.9710purine
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		7.110isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
n(6),n(6)-dimethyladenine
N(6),N(6)-dimethyladenine : A tertiary amine that is adenine substituted at N-6 by geminal methyl groups.		1.9710tertiary amine
fasudil
fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.		2.0610isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine
[no description available]		1.9710pyrazoles;
ring assembly
salicylamide
salamide: a major impurity of hydrochlorothiazide; structure in first source		2.0610phenols;
salicylamides		antirheumatic drug;
non-narcotic analgesic
sq 22536
9-(tetrahydrofuryl)adenine : A nucleoside analogue that is adenine in which the nitrogen at position 9 has been substituted by a tetrahydrofuran-2-yl group. It is an adenylate cyclase inhibitor.		1.9710nucleoside analogue;
oxolanes		EC 4.6.1.1 (adenylate cyclase) inhibitor
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		2.3720aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
benzimidazole
1H-benzimidazole : The 1H-tautomer of benzimidazole.		2.0610benzimidazole;
polycyclic heteroarene
biguanides
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.. biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.		6.9410guanidines
adenosine diphosphate
Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.		1.9710adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		1.9710adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
2-methylquinoline
2-methylquinoline: RN given refers to parent cpd. methylquinoline : Any member of the class of quinolines carrying at least one methyl substituent.. quinaldine : A quinoline compound in which the quinoline skeleton is substituted at C-2 with a methyl group.		1.9410quinolines
acetophenone
acetophenone : A methyl ketone that is acetone in which one of the methyl groups has been replaced by a phenyl group.		2.0610acetophenonesanimal metabolite;
photosensitizing agent;
xenobiotic
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.1110mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
isoquinoline
[no description available]		2.0610azaarene;
isoquinolines;
mancude organic heterobicyclic parent;
ortho-fused heteroarene
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		6.45310azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		2.0610indazole
benzofuran
benzofuran: RN & structure given in first source. 1-benzofuran : A benzofuran consisting of fused benzene and furan rings. It is the parent compound of the class of 1-benzofurans.		7.17101-benzofurans;
benzofuran
2-aminopurine
2-Aminopurine: A purine that is an isomer of ADENINE (6-aminopurine).. aminopurine : Any purine having at least one amino substituent.. 2-aminopurine : The parent compound of the 2-aminopurines, comprising a purine core carrying an amino substituent at the 2-position.		1.97102-aminopurines;
nucleobase analogue		antimetabolite
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		1.9710
4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine
4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine: structure in first source		1.9610
9-benzyladenine
[no description available]		1.9710
rhodium
Rhodium: A hard and rare metal of the platinum group, atomic number 45, atomic weight 102.905, symbol Rh.. rhodium atom : A cobalt group element atom of atomic number 45.		2.1110cobalt group element atom
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		1.9710adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
benzylaminopurine
benzylaminopurine: a plant growth regulator. N-benzyladenine : A member of the class of 6-aminopurines that is adenine in which one of the hydrogens of the amino group is replaced by a benzyl group.		1.97106-aminopurinescytokinin;
plant metabolite
2,4(1h,3h)-quinazolinedione
2,4(1H,3H)-quinazolinedione: structure given in first source		2.3620
2,4-diaminoquinazoline
[no description available]		2.6530
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.15101,2,3-triazole
4-aminopyrimidine
[no description available]		1.9710aminopyrimidine
9-methyladenine
9-methyladenine : Adenine substituted with a methyl group at position N-9.		1.9710methyladeninemetabolite
6-methoxypurine
6-methoxypurine: structure in first source		1.9710
7-methyladenine
7-methyladenine: potential marker for monitoring exposure to methylatingcarcinogens. 7-methyladenine : Adenine substituted with a methyl group at position N-7.		1.9710methyladeninemetabolite
1-aminoisoquinoline
[no description available]		1.9710
4-aminopyrazolo(3,4-d)pyrimidine
4-aminopyrazolo(3,4-d)pyrimidine: adenine analog which suppresses growth of E coli & Bacillus cereus; inhibits cell growth & purine biosynthesis in rat hepatoma		1.9710
imidazo(1,2-a)pyridine
imidazo(1,2-a)pyridine: structure		2.0610
2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine
2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine: RN given refers to parent cpd; structure given in first source		1.9610
pam 1392
[no description available]		2.3620
wr 158122
WR 158122: structure		2.3620
wr 159412
[no description available]		2.3620
methotrexate
[no description available]		2.3720dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
2,4,6-triamino-5-chloroquinazoline
2,4,6-triamino-5-chloroquinazoline: antifolate drug; structure given in first source		2.3620
lapatinib
[no description available]		2.610furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.1710
3-deazaadenine
[no description available]		1.9710
y 27632
Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.		2.0610aromatic amide
ha 1100
HA 1100: intracellular calcium antagonist		2.0610
zd 6474
CH 331: structure in first source		2.0710aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
6-methylpurine
6-methylpurine : Purine bearing a methyl substituent at position 6.		1.9710purinesEC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor
bibw 2992
[no description available]		2.3110aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
piperidines
Piperidines: A family of hexahydropyridines.		2.0710
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		2.110
ribociclib
ribociclib: inhibits both CDK4 and CDK6		2.610
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		2.1710
1-methyladenine
1-methyladenine : Adenine substituted with a methyl group at position N-1.		1.9710
3-methyladenine
N3-methyladenine: structure in first source		1.9710
4-hydroxyquinazoline
4-oxo-3,4-dihydroquinazoline: structure in first source		2.3620quinazolines
5,8-dideazaisofolic acid
5,8-dideazaisofolic acid: structure given in first source		1.9510
ConditionIndicatedRelationship StrengthStudiesTrials
E coli Infections
[description not available]		02.4120
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		02.4120
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
American Trypanosomiasis
[description not available]		02.610
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.		02.610
Breast Cancer
[description not available]		07.9130
Carcinoma, Non-Small Cell Lung
[description not available]		02.610
Cancer of Kidney
[description not available]		02.610
Cancer of Lung
[description not available]		02.610
Malignant Melanoma
[description not available]		02.610
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.9130
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.610
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		02.610
Lung Neoplasms
Tumors or cancer of the LUNG.		02.610
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.610
Tuberculosis, Drug-Resistant
[description not available]		02.2510
Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.		02.2510
Invasiveness, Neoplasm
[description not available]		02.2510
Kahler Disease
[description not available]		02.3110
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		07.3110
Benign Neoplasms
[description not available]		04.1830
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		04.1830
Haemophilus Infections
Infections with bacteria of the genus HAEMOPHILUS.		02.110
Infections, Plasmodium
[description not available]		01.9410
Malaria, Avian
Any of a group of infections of fowl caused by protozoa of the genera PLASMODIUM, Leucocytozoon, and Haemoproteus. The life cycles of these parasites and the disease produced bears strong resemblance to those observed in human malaria.		01.9410
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		06.9410
Colorectal Cancer
[description not available]		02.3110
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.3110